USFDA Guidance For Industry - PSUR

Guidance for Industry
Postmarketing Safety Reporting

for Human Drug and Biological
Products Including Vaccines
DRAFT GUIDANCE
This guidance document is being distributed for comment purposes only.
Comments and suggestions regarding this draft document should be submitted within 60
days of publication in the Federal Register of the notice announcing the availability of the
draft guidance. Submit comments to Dockets Management Branch (HFA-305), Food and
Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20857. All comments
should be identified with the docket number listed in the notice of availability that publishes
in the Federal Register.
For questions on the content of the draft document contact (CDER) Min Chen, 301-8273169 (phone); 301-827-5190 (fax), or (CBER) Miles Braun, 301-827-3974 (phone); 301827-3529 (fax).
U.S. Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
March 2001
Guidance for Industry

Postmarketing Safety Reporting
for Human Drug and Biological
Products Including Vaccines
Additional copies are available from:
Drug Information Branch (HFD-210)

5600 Fishers Lane, Rockville, MD 20857
(Tel) 301-827-4570
Internet at http://www.fda.gov/cder/guidance/index.htm
or
Office of Communication, Training and Manufacturers Assistance (HFM-40)
1401 Rockville Pike, Rockville, MD 20852-1448
(Fax) 1-888-CBERFAX or 301-827-3844
(Voice Information) 1-800-835-4709 or 301-827-1800
Internet at http://www.fda.gov/cber/guidelines.htm
U.S. Department of Health and Human Services

March 2001
TABLE OF CONTENTS
I.
INTRODUCTION..................................................................................................................................................................1
A.
B.
C.
II.
W HAT DOES THIS GUIDANCE DISCUSS?.......................................................................................................................... 1

W HAT DOES THIS GUIDANCE NOT DISCUSS?................................................................................................................. 2
GOOD GUIDANCE PRACTICES ............................................................................................................................................. 2
BACKGROUND....................................................................................................................................................................3
A.
B.
C.
FINAL RULES ....................................................................................................................................................................... 3

GUIDANCES ......................................................................................................................................................................... 3
PROPOSED RULES ............................................................................................................................................................... 4
III.
WHO MUST REPORT.........................................................................................................................................................4
IV.
WHAT DO I REPORT? .......................................................................................................................................................5
A.
B.
V.
TYPE OF A DVERSE EXPERIENCES ..................................................................................................................................... 6

DATA ELEMENTS TO INCLUDE IN A POSTMARKETING INDIVIDUAL CASE SAFETY REPORT ......................................... 8
TYPE OF REPORTS ............................................................................................................................................................9
A.
B.
C.
D.
VI.
A.
B.
C.
D.
E.
F.
G.
H.
I.
J.
K.
L.
M.
N.
O.
P.
Q.
R.
15-DAY REPORTS OF SERIOUS , UNEXPECTED A DVERSE EXPERIENCES ........................................................................ 9

PERIODIC REPORTS .......................................................................................................................................................... 11
FOLLOWUP REPORTS ....................................................................................................................................................... 15
DISTRIBUTION REPORTS FOR BIOLOGICAL PRODUCTS INCLUDING VACCINES ............................................................ 18
SPECIAL REPORTING SITUATIONS .....................................................................................................................18
SCIENTIFIC LITERATURE REPORTS ................................................................................................................................. 18
POSTMARKETING, CLINICAL TRIAL, OR SURVEILLANCE STUDIES ................................................................................ 19
FOREIGN REPORTS ........................................................................................................................................................... 20
DEATH REPORTS .............................................................................................................................................................. 20
OVERDOSE REPORTS........................................................................................................................................................ 20
LACK OF EFFECT REPORTS ............................................................................................................................................. 21
INFORMATION ON THE INTERNET .................................................................................................................................... 21
PEDIATRIC PATIENTS ....................................................................................................................................................... 21
PRESCRIPTION DRUGS M ARKETED FOR HUMAN USE W ITHOUT AN A PPROVED A PPLICATION................................ 22
A NOTHER A PPLICANT =S PRODUCT ................................................................................................................................. 22
M ULTIPLE SUSPECT PRODUCTS ..................................................................................................................................... 22
SUSPECT DRUGS WITH M ULTIPLE NDA S OR ANDA S BY THE SAME A PPLICANT ................................................... 23
TWO OR M ORE M ARKETERS OF A PRODUCT ................................................................................................................ 23
UNAPPROVED INDICATIONS ............................................................................................................................................. 23
PRODUCT INTERACTIONS ................................................................................................................................................ 23
REPORTS FROM THE FDA ............................................................................................................................................... 23
PRODUCT DEFECTS.......................................................................................................................................................... 24
REPORTING A MBIGUITIES ................................................................................................................................................ 24
VII.
CODING OF ADVERSE EXPERIENCES IN INDIVIDUAL CASE SAFETY REPORTS ..................................24
VIII.
REPORTING FORMATS.............................................................................................................................................25
A.
B.
C.
D.
FDA FORM 3500A........................................................................................................................................................... 25

VAERS FORM FOR VACCINES ......................................................................................................................................... 28
CIOMS I FORM FOR FOREIGN A DVERSE EXPERIENCES ................................................................................................ 29
DISTRIBUTION REPORTS FOR BIOLOGICAL PRODUCTS INCLUDING VACCINES ............................................................ 29
E.
IX.
A.
B.
ELECTRONIC SUBMISSIONS .............................................................................................................................................. 30

HOW AND WHERE TO SUBMIT POSTMARKETING SAFETY REPORTS.........................................................30
HUMAN DRUG PRODUCTS ............................................................................................................................................... 30
HUMAN BIOLOGICAL PRODUCTS AND VACCINES ........................................................................................................... 31
X.
WRITTEN PROCEDURES FOR POSTMARKETING SAFETY REPORTING.......................................................31
XI.
REQUESTS FOR WAIVERS TO POSTMARKETING SAFETY REPORTING REQUIREMENTS ....................32

A.
B.
C.
D.
XII.
SUBMISSION OF FDA FORM 3500A FOR NONSERIOUS , EXPECTED A DVERSE EXPERIENCES ..................................... 32
SUBMISSION OF PSUR FORMAT FOR THE PERIODIC REPORT ....................................................................................... 32
SUBMISSION DATE AND FREQUENCY FOR PSUR REPORTS .......................................................................................... 33
HOW AND W HERE TO SUBMIT W AIVER REQUESTS ...................................................................................................... 34
VALIDATION OF ADVERSE EXPERIENCE COMPUTER SYSTEMS ..............................................................34
APPENDIX A: GLOSSARY.......................................................................................................................................................35
APPENDIX B: REPORT CHECKLIST.....................................................................................................................................38
APPENDIX C: FDA FORM 500A................41
APPENDIX D: FORM VAERS-1............43
APPENDIX E: CIOMS 1 FORM.................45
APPENDIX F: ONE-PAGE FDA FORM 3500A................46
Draft Not for Implementation
Guidance for Industry1
1
2
Postmarketing Safety Reporting for Human Drug and

Biological Products Including Vaccines
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
This draft guidance, when finalized, represents the Food and Drug Administration's (FDAs)
current thinking on this topic. It does not create or confer any rights for or on any person and
does not operate to bind FDA or the public. An alternative approach may be used if such
approach satisfies the requirements of the applicable statutes and regulations.
I.
INTRODUCTION
This guidance is intended to assist applicants and other responsible parties in fulfilling the
FDA=s existing postmarketing safety reporting requirements for human marketed drug and
biological products at 21 CFR 310.305, 314.80, 314.98, 600.80, and 600.81.2 Under
these regulations, postmarketing safety reports must be submitted to the Agency for the
following:
1. Serious and unexpected adverse experiences from all sources (domestic and
foreign)
2. Spontaneously reported adverse experiences that occur domestically and that are:
A.
Serious and expected

Nonserious and unexpected
Nonserious and expected
What Does This Guidance Discuss?

This guidance discusses the following postmarketing reports:
This guidance has been prepared by FDA=s Safety Reporting Regulations Working Group, which includes
representatives from the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation
and Research (CBER).
The FDA is planning to propose revisions to these regulations (see section II.C in this guidance). As these
proposals are finalized the Agency will revise this guidance to provide industry with assistance in fulfilling the
new regulatory requirements.

37
38
39
40
41
42
43
44
15-Day Reports of Serious, Unexpected Adverse Experiences

Periodic Reports
Followup Reports
Distribution Reports for Biological Products Including Vaccines
This guidance addresses the following regulations for the following products.3
Regulation
21 CFR 310.305
21 CFR 314.80
21 CFR 314.98
21 CFR 600.80
21 CFR 600.81
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
Product
Prescription drugs marketed for human use without an
an approved application
Human drugs with approved NDAs
Human drugs with approved ANDAs
Human biological products with approved BLAs
Human biological products with approved BLAs
If you believe the procedures described in this guidance are inapplicable to a particular
product or that other procedures are appropriate, you should discuss the matter with the
Agency to ensure that your procedures comply with applicable statutes and regulations.
B.
What Does This Guidance Not Discuss?

This guidance does not discuss the following:
IND Safety Reports (21 CFR 312.32)4

Safety Update Reports for Drugs (21 CFR 314.50(d)(5)(vi)(b))
Approved NDA Annual Reports (21 CFR 314.81(b)(2))
Approved BLA Annual Reports (21 CFR 601.28)
This guidance does not apply to the following products:
C.
In vitro diagnostic products

Whole blood or its components
Product manufacturing defects (unless the defect is associated with an
adverse experience in humans)
Good Guidance Practices
The Agency's good guidance practices (GGPs) regulation5 does not allow the use of
mandatory language in guidances unless it is used to describe regulatory requirements. In
3
NDA means new drug application, ANDA means abbreviated new drug application, and BLA means
biologics license application
4
IND means investigational new drug application

70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
most guidances, we provide the related cite whenever mandatory language is used to
indicate the basis for the use of such language. This guidance discusses regulatory
requirements in great detail. To avoid including the same regulatory cites repeatedly and
to make the guidance user friendly, we will indicate at the beginning of those sections that
include extensive discussions of regulatory requirements which cites are particularly
relevant. The use of mandatory language (e.g., must, have to, required) will signify a
regulatory requirement while the use of words such as should and recommend will indicate
Agency policy.
II.
BACKGROUND
The FDA has undertaken a major effort to clarify and revise its regulations regarding preand postmarketing safety reporting requirements for human drug and biological products.
To date, the Agency has issued a number of final rules and guidances for industry on this
topic; several proposed rules are under development.
A.
Final Rules
Expedited Safety Reports for Human Drug and Biological Products
In the Federal Register of October 7, 1997 (62 FR 52237), the FDA published a
final rule amending its regulations for expedited safety reporting to implement
certain definitions, reporting periods, and formats recommended by the International
Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH). These recommendations are discussed in
the ICH guidance E2A Clinical Safety Data Management: Definitions and
Standards for Expedited Reporting; March 1, 1995.
Postmarketing Expedited Increased Frequency Reports for Human Drug and

Biological Products
In the Federal Register of June 25, 1997 (62 FR 34166), the FDA published a final
rule revoking requirements to submit postmarketing increased frequency reports to
the Agency in an expedited manner for human drug and biological products.
B.
Guidances
With regard to postmarketing safety reporting for human drug and biological products, the
FDA has made three final guidances available:
Postmarketing Reporting of Adverse Drug Experiences (March 1992)
The Agency's regulation on good guidance practices published on September 19, 2000 (21 CFR 10.115; 65
FR 56468).

112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
Guideline for Adverse Experience Reporting for Licensed Biological

Products (October 1993)
Postmarketing Adverse Experience Reporting for Human Drug and

Licensed Biological Products: Clarification of What to Report (August 27,
1997).
When finalized, this guidance will replace the three guidances listed above and will reflect
the new regulatory requirements in the final rules of June 25, 1997, and October 7, 1997.
C.
Proposed Rules
The Agency currently is in the process of developing proposed rules to further amend its
safety reporting requirements for human drug and biological products. Many of the
provisions in these proposed rules will be based on recommendations developed by ICH.
For instance, the Agency is planning to propose additional amendments to its expedited
safety reporting regulations based on the ICH E2A guidance.
In addition, the FDA is planning, as indicated in the final rule of October 7, 1997, to
repropose amendments to its postmarketing periodic safety reporting requirements that
were initially proposed in the Federal Register of October 27, 1994 (59 FR 54046). The
new postmarketing periodic safety reporting proposals will be based on recommendations
in the ICH guidance E2C Clinical Safety Data Management: Periodic Safety Update
Reports for Marketed Drugs (May 19, 1997).
The Agency also is planning to issue a proposal requiring the electronic submission of
postmarketing safety reports consistent with recommendations developed by ICH.6
As these proposed rules are finalized, this postmarketing safety reporting guidance for
human drug and biological products will be revised to provide industry with assistance in
fulfilling the new regulatory requirements.
III.
WHO MUST REPORT
According to the regulations, the following persons have postmarketing safety reporting
responsibilities:
Manufacturers are required to submit postmarketing expedited safety reports to the

FDA for prescription drug products marketed for human use without an approved
application ( 310.305).
See advance notice of proposed rulemaking on electronic reporting of postmarketing adverse drug
reactions; request for comments, 63 FR 59746, November 5, 1998.

154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
Applicants (individual or corporate entity that holds an NDA or ANDA) are required
to submit postmarketing safety reports to the FDA for human drug products with
approved NDAs ( 314.80) and ANDAs ( 314.98).
Licensed manufacturers (individual or corporate entity that holds a BLA) are

required to submit postmarketing safety reports to the FDA for human licensed
biological products with approved BLAs ( 600.80 and 600.81).
Any person whose name appears on the label of a marketed drug as its packer or
distributor ( 310.305(c)(1)(i)) or manufacturer, packer, or distributor
( 314.80(c)(1)(iii)) has postmarketing safety reporting responsibilities.
Any person whose name appears on the label of a licensed biological product as its
manufacturer, packer, distributor, shared manufacturer, joint manufacturer, or any
other participant involved in divided manufacturing has postmarketing safety
reporting responsibilities ( 600.80(c)(1)(iii)).
For the purposes of this guidance, the term applicant includes all persons with
postmarketing safety reporting responsibilities under 310.305, 314.80, 314.98, 600.80,
and 600.81.
According to the regulations at 310.305(d), 314.80(f), and 600.80(f), if an applicant
becomes aware of a reportable adverse experience, the applicant is responsible for
preparing a postmarketing safety report and submitting it to the FDA. Applicants should
not assume that their responsibilities are fulfilled if they ask the person who pointed out a
reportable adverse experience to submit a safety report to the FDA.
IV.
WHAT DO I REPORT?
The following paragraphs discuss the types of adverse experiences that must be reported
to the FDA under 310.305, 314.80, 314.98, and 600.80. This section also describes
the minimum data elements that should be included in an individual case safety report.
An adverse experience is any undesirable event that is associated with the use of a drug
or biological product in humans whether or not considered product-related by the
applicant.7 An individual case safety report describes an adverse experience(s) for a
patient or subject. Individual case safety reports of domestic adverse experiences for
marketed human drug and biological products, except vaccines, must be submitted to the
FDA on FDA Form 3500A; a Vaccine Adverse Event Reporting System (VAERS) form
must be used for adverse experiences associated with the use of vaccines. Individual
case safety reports of foreign adverse experiences can be submitted on FDA Form 3500A
7
See Appendix A for definition of adverse experience. (See also '' 310.305(b), 314.80(a) and 600.80(a).)

197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
(VAERS form for vaccines) or, if preferred, on a Council for International Organizations for
Medical Sciences (CIOMS) I form. See section VIII in this guidance for discussion of
reporting formats for individual case safety reports.
A.
Type of Adverse Experiences

1.
Adverse Experiences that are Serious and Unexpected from All Sources
(Domestic and Foreign)8
Serious and unexpected adverse experiences from all sources, whether domestic
or foreign, must be submitted to the FDA. Possible sources include, for example,
scientific literature, postmarketing studies, or commercial marketing experience.
Scientific literature reports include published and unpublished scientific papers that
are known to the applicant (see section VI.A in this guidance for reporting of
adverse experiences from the scientific literature).
Postmarketing studies include in vitro, animal, clinical, and epidemiological or
surveillance investigations (see section VI.B in this guidance for reporting of
adverse experiences from studies). Adverse experiences from studies must only
be submitted to the FDA if the applicant believes that there is a reasonable
possibility that the drug or biological product caused the adverse experience (see
310.305(c)(1)(ii), 314.80(e)(1) and 600.80(e)(1)).
2.
Other Spontaneously Reported Adverse Experiences (Domestic Only)9
Adverse experiences occurring in the United States from commercial marketing

experience must be submitted to the FDA if they are spontaneously reported to
applicants and are:
serious and expected

nonserious and unexpected, or
nonserious and expected
Applicants can request a waiver of the requirement to submit individual case safety
reports of nonserious, expected adverse experiences for drugs and certain
biological products (see section XI.A in this guidance on waiver requests).
3.
Serious Adverse Experiences10
The requirements for reports of serious, unexpected adverse experiences can be found in 310.305(c),
314.80(c)(1) and 600.80(c)(1).
9
The requirements for reports describing these adverse experiences can be found in 314.80(c)(2) and
600.80(c)(2).

236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
The outcome of an adverse experience must be determined before a report can be

identified as serious. A serious report must have one or more of the following
outcomes:
Death
Life-threatening adverse experience
Initial inpatient hospitalization or prolongation of hospitalization
Significant or persistent disability/incapacity
Congenital anomaly/birth defect (including that occurring in a fetus)
Important medical event based upon appropriate medical judgment that may
jeopardize the patient or subject and may require medical or surgical
intervention to prevent one of the other outcomes listed in the definition of
serious.
A patient admitted to a hospital for 1 or more days as a result of an adverse

experience, even if released on the same day, would qualify for the initial inpatient
hospitalization outcome. An emergency room visit that results in admission to the
hospital would also qualify for the initial inpatient hospitalization outcome.
However, emergency room visits that do not result in admission to the hospital
would not qualify for this outcome and, instead, should be evaluated for one of the
other outcomes in the definition of serious (e.g., life-threatening adverse
experience, important medical event).
Persons incarcerated because of actions allegedly caused by a drug (e.g.,
psychotropic drugs and rage reactions) have sustained a substantial disruption in
their ability to conduct normal life functions. Thus, these adverse experiences would
qualify for the significant or persistent disability/incapacity outcome.
Important medical events would include allergic bronchospasm requiring intensive
treatment in an emergency room or at home, blood dyscrasias or convulsions that
do not result in inpatient hospitalization, or the development of drug dependency or
drug abuse. Applicants should mark the "other" box in item B2 of FDA Form 3500A
for adverse experiences identified as important medical events.
Applicants should actively seek the outcome for a suspected serious adverse
experience reported to them. If unable to initially determine the outcome for an
adverse experience, an applicant should continue to actively seek information in an
attempt to determine an outcome. For a serious adverse experience that was not
initially reported to the applicant by a health care professional (e.g., report from a
consumer), the applicant should actively pursue contacting the health care
10
See Appendix A for definition of serious adverse experience. (See also 310.305(b), 314.80(a) and
600.80(a).)

277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
professional associated with the care of the patient to gather further medical
perspective on the case.
4.
Unexpected and Expected Adverse Experiences11
The current FDA-approved labeling for the human drug or biological product should
be used as the reference document to determine whether an adverse experience is
unexpected or expected. An adverse experience would be considered unexpected
if it is not included in the products current FDA-approved labeling and expected if it
is included in this document.
5.
Spontaneous Report12
Spontaneous reports are unsolicited communications from individuals (e.g., health

care professional, consumer) to applicants that concern adverse experiences.
Spontaneous reports should not include adverse experiences identified from
information solicited by applicants such as individual cases or findings derived from
a study (e.g., any organized data collection scheme).
B.
Data Elements to Include in a Postmarketing Individual Case Safety Report
Before considering any clinical incident for submission to the FDA in an individual case
safety report, applicants should, at a minimum, have knowledge of the following four data
elements:
1.
2.
3.
4.
An identifiable patient
An identifiable reporter
A suspect drug or biological product
An adverse experience or fatal outcome suspected to be due to the suspect
drug or biological product
If any one of these basic elements remains unknown after being actively sought by the
applicant, a report on the incident should not be submitted to the FDA because reports
without such information make interpretation of their significance difficult, at best, and
impossible, in most instances. Instead, the applicant should maintain records of its efforts
to obtain the basic elements for an individual case in its corporate drug or biological
product safety files. If an applicant submits a report to the FDA that lacks any of the four
basic elements, it will be returned to the applicant marked insufficient data for a report.
11
See Appendix A for definitions of unexpected and expected adverse experiences. (See also
310.305(b), 314.80(a) and 600.80(a).)
12
See Appendix A for definition of spontaneous report.
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
An applicant that is actively seeking information on an adverse experience should use

direct verbal contact with the initial reporter of the adverse experience (e.g., in person, by
telephone or other interactive means such as a videoconference). The applicant should not
merely send the initial reporter a letter requesting information concerning the adverse
experience. Applicants should use a health care professional (e.g., physician, physician
assistant, dentist, pharmacist, nurse) for contacts with initial reporters because such
persons should be able to understand the medical consequences of the case and ask
appropriate questions to acquire relevant information rapidly to determine the significance
of the case.
With regard to an identifiable patient, reports of the type Asome patients got anaphylaxis@
should be excluded until further information about the patients is obtained. A report stating
that Aan elderly woman had anaphylaxis@ or a Ayoung man experienced anaphylaxis@ should
be included because there is enough information to suspect that specific patients were
involved. Patients should not be identified by name or address. Instead, the applicant
should assign a unique code (e.g., patient initials) to each report.
For spontaneous reports, the applicant should assume that an adverse experience or fatal
outcome was suspected to be due to the suspect drug or biological product (implied
causality). For clinical studies, an adverse experience or fatal outcome need not be
submitted to the FDA unless the applicant concludes that there is a reasonable possibility
that the product caused the adverse experience or fatal outcome (see 310.305(c)(1)(ii),
314.80(e)(1) and 600.80(e)(1)). An adverse experience should, at a minimum, consist of
signs (including abnormal laboratory findings, if appropriate), symptoms, or disease
diagnosis (including any colloquial descriptions obtained) for purposes of reporting. Thus,
a report stating that a patient Aexperienced unspecified injury,@ or a patient Asuffered
irreparable damages@ should not be included until more specific information about the
adverse experience can be determined.
V.
TYPE OF REPORTS
The following paragraphs discuss the types of postmarketing safety reports that must be
submitted to the FDA based on the regulations as listed.
A.
15-Day Reports of Serious, Unexpected Adverse Experiences13
Individual case safety reports of serious, unexpected adverse experiences from all sources
(domestic and foreign) must be reported to the FDA as soon as possible, but in no case
later than 15 calendar days of initial receipt of the information by the applicant. See section
VIII in this guidance for discussion of reporting formats for individual case safety reports.
13
The requirements for 15-Day Reports can be found in 310.305(a), (c)(1)(i) and (d)(1), 314.80(c)(1)(i) and
(f)(1), and 600.80(c)(1)(i) and (f)(1).

357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
An applicant should not wait for the initial reporter of a serious, unexpected adverse
experience to send them written information about the experience before submitting a 15day report to the FDA. An applicant can and should submit a 15-day report to the FDA
based only on verbal information.
1.
Determination of 15-Day Reporting Period
Serious, unexpected adverse experiences must be submitted to the FDA no later

than 15 calendar days of initial receipt of the information by the applicant. For
reporting purposes, this information should include, at a minimum, the four basic
elements (i.e., an identifiable patient, an identifiable reporter, a suspect drug or
biological product, and a serious, unexpected adverse experience). The date the
company has knowledge of these four basic elements should be entered into item
G4 of FDA Form 3500A or Box 25 of the VAERS form (i.e., this date represents
Day 0 of the 15-day time clock).
If the 15th calendar day occurs on a weekend or U.S. Federal holiday, the 15-day
report should be submitted the first working day after the weekend or U.S. Federal
holiday.
The applicant should exercise due diligence to acquire all the information for an
individual case safety report immediately upon receipt of a suspected serious,
unexpected adverse experience (e.g., completion of all the applicable elements on
FDA Form 3500A). The applicant should maintain records of its efforts to obtain
this information and should include in the narrative section of FDA Form 3500A (i.e.,
item B5), a chronological description of these efforts if there is a delay in obtaining
such information.
When an applicant receives a report of a serious, unexpected adverse experience
but it is not possible to complete all the applicable elements for an individual case
safety report within 15 calendar days, a preliminary report that contains at least the
four basic elements should be submitted. Additional followup information should be
actively sought and submitted within 15 calendar days after obtaining the new
information (see section V.C in this guidance for discussion of followup reports).
For foreign reports, the 15-day time clock begins when the applicant or its foreign
affiliate has received the four basic elements for a 15-day report. Applicants should
therefore establish effective mechanisms to ensure rapid information transfer from
their foreign affiliates.
2.
Supporting Documentation
For individual case safety reports of serious, unexpected adverse experiences, the
FDA encourages applicants to include relevant hospital discharge summaries and
autopsy reports/death certificates. Applicants should also include in their report a
10

402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
list of other relevant documents (e.g., medical records, relevant laboratory data,
electrocardiograms, and other concise critical clinical data) maintained in their
corporate drug or biological product safety files. The FDA can request that copies
of one or more of these documents be provided to the Agency. Applicants should
submit copies of these documents to the Agency within 5 calendar days after
receipt of the request.
3.
Report Identification
Fifteen-day reports must be submitted in duplicate under separate cover

prominently identified as "15-Day Alert Report." For this purpose, the 15-Day Alert
Report identification should be included on the outside envelope.
For prescription drugs marketed for human use without an approved application, a
single copy of the 15-day report and a copy of the U.S. labeling must be submitted.
These reports should be marked on the outside envelope with "15-Day Alert Report
- 310.305."
Multiple 15-day reports and 15-day followup reports can be submitted in the same
envelope, but they should not be stapled together (see section V.C for discussion of
followup reports).
B.
Periodic Reports14
The following paragraphs discuss the reporting frequency for submission of periodic
reports and the content of these reports. See section XI in this guidance for requests for
waivers of the requirement to submit postmarketing periodic safety reports (e.g., waiver to
use periodic safety update report (PSUR) format recommended by ICH for periodic report
instead of format described in the regulations, waiver to submit individual cases of
nonserious, expected adverse experiences in periodic report).
1.
Timing of Postmarketing Periodic Reports
Postmarketing periodic reports are required to be submitted to the FDA for each
approved NDA, ANDA, and BLA and are due quarterly for the first 3 years after U.S.
approval of the application and annually thereafter. If marketing is delayed, these
reports should still be submitted quarterly for the first 3 years of marketing. Upon
written notice, the FDA may extend or reestablish the requirement that an applicant
submit quarterly reports or require that the applicant submit periodic reports at
different time intervals.
Periodic reports due quarterly must be submitted within 30 calendar days of the last
day of the reporting quarter. Reports due annually must be submitted each year
14
The requirements for periodic reports can be found in '' 314.80(c)(2) and 600.80(c)(2).
11

445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
within 60 calendar days of the anniversary date of U.S. approval of the application
for the drug or biological product (i.e., NDA, ANDA, BLA).
Periodic submissions should be clearly marked "Periodic Adverse Experience
Submission" on the front cover of each volume. Each page of the periodic report
should be numbered and include the name and NDA or ANDA number if the
periodic report is for a drug product; the name and submission tracking number
(STN) should be used if the periodic report is for a biological product (a STN for a
biological product can be found on the Internet at www.fda.gov/cber/stn/stn.htm).
2.
Content of a Postmarketing Periodic Report
The regulations require a postmarketing periodic report to contain:
a narrative summary and analysis of the information in the report and an analysis
of the 15-day Alert reports submitted during the reporting interval
an FDA Form 3500A for each spontaneously reported adverse experience
occurring in the United States that was not reported in a 15-day Alert report
a history of actions taken since the last report because of adverse experiences.
The information contained within a postmarketing periodic report should be divided

into four sections in the order described below and should be clearly separated by
an identifying tab. If information for one of these sections is not included, the
applicant should simply explain why the information is not provided.
a.
Section 1: Narrative summary and analysis
A narrative summary and analysis of the information in the postmarketing

periodic report and an analysis of the 15-day reports (i.e., serious,
unexpected adverse experiences) submitted during the reporting period
must be provided and should include:
The number of non-15-day15 initial adverse experience reports and

the number of non-15-day followup reports contained in this periodic
report and the time period covered by the periodic report.
A line listing of the 15-day reports submitted during the reporting

period. This line listing should include the manufacturer report
number, adverse experience term(s), and the date the 15-day report
was sent to the FDA.
15
These include serious and expected adverse experiences, nonserious and unexpected adverse
experiences, and nonserious and expected adverse experiences.
12
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
A summary tabulation by body system (e.g., cardiovascular, central

nervous system, endocrine, renal) of all adverse experience terms
and counts of occurrences submitted during the reporting period. The
information should be taken from :
-
15-day reports submitted to the FDA;

non-15-day reports submitted in the periodic report;
reports forwarded to the applicant by the FDA; and
any nonserious, expected adverse experiences not submitted to
the FDA but maintained on file by the applicant.
For the adverse experience term product interaction, the interacting

products should be identified in the tabulation.
A summary listing of the adverse experience reports in which the drug

or biological product was listed as one of the suspect products, but
the report was filed to another NDA, ANDA, or BLA held by the
applicant.
A narrative discussion of the clinical significance of the 15-day reports

submitted during the reporting period and of any increased reporting
frequency of serious, expected adverse experiences when, in the
judgment of the applicant, it is believed the data reflect a clinically
meaningful change in adverse experience occurrence. This narrative
should assess clinical significance by type of adverse experience,
body system, and overall product safety relating the new information
received during this reporting period to what was already known
about the product. The narrative should also state what further
actions, if any, the applicant plans to undertake based on the
information gained during the reporting period and include the time
period for completing the actions (i.e., when the applicant plans to
start and finish the action and submit the information to the Agency).
The narrative discussion should indicate, based on the information

learned during the reporting period, whether the applicant believes
either that (1) no change in the products current approved labeling is
warranted or (2) there are safety-related issues that need to be
addressed in the approved product labeling. If changes in the
approved product labeling are under consideration by the FDA, the
applicant should state in the narrative the date and number of the
supplemental application submitted to address the labeling changes.
13

528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
b.
Section 2: Narrative discussion of actions taken
A narrative discussion of actions taken must be provided, including any

labeling changes and studies initiated since the last periodic report. This
section should include:
A copy of current U.S. product labeling
A list of any labeling changes made during the reporting period
A list of studies initiated
A summary of important foreign regulatory actions (e.g., new

warnings, limitations in the indications and use of the product)
Any communication of new safety information (e.g., a Dear Doctor

letter)
c.
Section 3: Index line listing
An index line listing of FDA Form 3500As or VAERS forms included in

section 4 of the periodic report must be provided. The line listing for each
FDA Form 3500A or VAERS form submitted should include:
Manufacturer report number
Adverse experience term(s)
Page number of FDA Form 3500A or VAERS form as located in the

periodic report
Identification of interacting products for any product interaction listed

as an adverse experience.
d.
Section 4: FDA Form 3500As or VAERS forms
FDA Form 3500As or VAERS forms must be provided for the following
spontaneously reported adverse experiences that occurred in the United
States during the reporting period:
Serious and expected
Nonserious and unexpected
14

572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
Nonserious and expected
Applicants are encouraged to request a waiver of the requirement to submit

individual case safety reports of nonserious, expected adverse experiences
for drugs and certain biological products as described below (see section
XI.A in this guidance).
Adverse experiences due to a failure to produce the expected
pharmacologic action (i.e., lack of effect) should be included in this section
(see section VI.F in this guidance).
For individual case safety reports of serious, expected adverse experiences,
the FDA encourages applicants to include relevant hospital discharge
summaries and autopsy reports/death certificates, as well as lists of other
relevant documents as described for 15-day reports of serious, unexpected
adverse experiences (see section V.A.2 in this guidance).
Initial non-15 day reports should be included in the periodic report in a
separate section from non-15 day followup reports (see the following section
V.C for discussion of non-15 day followup reports). All initial and followup
information obtained for an adverse experience with a given periodic
reporting period should be combined and submitted in the periodic report as
one initial non-15 day report (i.e., an initial non-15 day report and a non-15
day followup report describing the same adverse experience should not be
submitted in the same periodic report).
An FDA Form 3500A or VAERS form for a serious, unexpected adverse
experience should not be included in a periodic report because this adverse
experience should have been previously submitted to the FDA as a 15-day
report.
If no adverse experiences were identified for the human drug or biological product
for the time period involved and no regulatory actions concerning safety were taken
anywhere in the world where the product is marketed, the periodic report should
simply state this and be submitted to the FDA along with a copy of the current U.S.
labeling.
C.
Followup Reports16
The following paragraphs discuss the content of and reporting considerations for 15-day
followup reports that are submitted in an expedited manner and non-15 day followup
reports that are submitted as part of a postmarketing periodic report. A followup report
provides information about an adverse experience that has been previously reported as an
16
The requirements for followup reports can be found in '' 310.305(c)(2), 314.80(c) and 600.80(c).
15

615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
initial report with a unique manufacturer report number. The followup report should be
identified with the same unique manufacturer report number as the initial report.
A 15-day followup report must be submitted within 15 calendar days of receipt of new
information on a 15-day report. Followup information to adverse experiences submitted
initially in a periodic report can be submitted in the next periodic report.
1.
Content of Followup Reports
A followup report should provide a complete picture of the current understanding of

the adverse experience. Relevant information from the initial report should be
combined with the followup information to present an accurate and comprehensive
description of the adverse experience as it is understood at the time of the followup.
Information from the initial report later found to be inaccurate should not be repeated
in the followup report. All new information including correction of previously
submitted inaccurate information that is included in a followup report should be
highlighted (e.g., with an asterisk, underlined).
The narrative section of the followup report should be concise (i.e., item B5 of FDA
Form 3500A) because the FDAs adverse event reporting database (AERS) is
limited for this section of the form.
For serious adverse experiences, applicants should exercise due diligence in
obtaining followup information for the purposes of completing all the applicable
elements for an individual case safety report (e.g., FDA Form 3500A). For adverse
experiences that are determined to be nonserious and for which the four basic
elements are known (see section IV.B), additional followup is not necessary.
Any attachments submitted with an initial report (e.g. scientific journal articles,
hospital discharge summaries) should not be resubmitted with a followup report.
2.
Reporting Considerations
A copy of the initial report or a previous followup report should not be sent with the
latest followup report. Fifteen-day followup reports should not be submitted in the
same envelope with periodic reports.
If the initial report was submitted as a 15-day report, the followup report should be
submitted as a 15-day followup report even if the followup information shows that the
adverse experience was expected or not serious. All subsequent followup reports
for adverse experiences that are expected or not serious should be submitted in
periodic reports. A 15-day followup report should be submitted if the adverse
experience is found to be serious and unexpected, even if the original report was
not submitted as a 15-day report.
16

660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
If a new adverse experience occurs that is associated with the initial adverse
experience, a followup report should be submitted. However, if the new adverse
experience is not associated with the initial adverse experience (e.g., occurs after a
subsequent administration of the product), an initial report with a new manufacturer
report number should be submitted for the new adverse experience. In these cases,
the applicant should consider the clinical relevance of the adverse experiences to
each other when determining whether an initial report or followup report should be
submitted.
Followup reports should not be submitted if additional relevant information is not
obtained for the adverse experience. However, as described in the regulations,
applicants should maintain records of their efforts to obtain additional information,
particularly for serious adverse experiences. FDA may request this documentation.
3.
Reporting Forms
For followup reports, particular attention should be paid to completing the following
items on FDA Form 3500A:
Item G3 - Mark health professional if at any time a health professional

provided information for the report.
Item G4 - Use the date the followup information was received by the
applicant.
Item G7- Mark followup, and indicate whether this is the 1st, 2nd, 3rd,
... followup report.
Item G9 - Use the same unique manufacturer report number assigned
to the initial report. This is essential to prevent duplicate counting of
reports and to ensure that the followup information is coupled with the
correct initial report.
For followup reports, particular attention should be paid to completing the following
items on the VAERS form for vaccines:
Top right - Indicate the name of the person who provided information
for the report.
Box 24 - Use the same manufacturer report number assigned to the
initial report. This is essential to prevent duplicate counting of reports
and to ensure that the followup information is coupled with the correct
initial report.
Box 25 - Use the date the followup information was received by the
applicant.
Box 27 - Mark followup, and indicate whether this is the 1st, 2nd, 3rd,
... followup report.
17

704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
4.
Report Identification
Fifteen-day followup reports must be submitted in duplicate under separate cover

prominently identified as "15-Day Alert Report-Followup." For this purpose, the 15Day Alert Report-Followup identification should be included on the outside
envelope.
D.
This section is based primarily on regulations in 600.81. These regulations only apply to
human biological products with approved BLAs. Unless otherwise notified by the Director,
Center for Biologics Evaluation and Research, an applicant must submit at periodic
intervals two copies of a report containing information about the quantity of the product
distributed domestically (including distributors) under the BLA.
Distribution reports are due within the first 6 months after approval of a BLA, and,
subsequently, at 6-month intervals. Upon written notice, the FDA can require that the
applicant submit reports under this section at alternate times.
The report must include the bulk lot, fill lot, and label lot numbers for the total number of
dosage units of each strength or potency distributed (e.g., 50,000 per 10-milliliter vials),
labeled date of expiration, and date of distribution of fill lot or label lot. The report must also
include information about any significant amount of a fill lot or label lot that may have been
returned. Disclosure of financial or pricing data is not required. According to the
regulations, the FDA can require submission of more detailed product distribution
information, if needed.
See section VIII.E in this guidance for a suggested reporting format for distribution reports.
VI.
SPECIAL REPORTING SITUATIONS
A.
Scientific Literature Reports17
Serious, unexpected adverse experiences reported in the scientific literature (or in an

unpublished scientific paper) that are known to the applicant must be submitted as 15-day
reports on an FDA Form 3500A or comparable format. Applicants can use literature
search services (e.g., Weekly Reactions) to identify adverse experiences in the scientific
literature. A copy of the article or manuscript must be attached to the completed FDA
Form 3500A; it is not sufficient to submit only abstracts of articles. All reports from the
scientific literature and unpublished scientific papers should be marked Literature in item
G3 of FDA Form 3500A.
17
The requirements for scientific literature reports can be found in '' 314.80(c)(1)(i), 314.80(d),
600.80(c)(1)(i), and 600.80(d).
18

746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
A separate FDA Form 3500A should be completed for each identifiable patient that
experiences a serious, unexpected adverse experience. Thus, if an article describes six
patients that experience a given serious, unexpected adverse experience, six FDA Form
3500As should be completed. In such cases, a copy of the article should be attached only
to one of the FDA Form 3500As. All other FDA Form 3500As submitted for the article
should reference the manufacturer report number of the FDA Form 3500A that has the
copy of the article attached.
If multiple products are mentioned in the article, an FDA Form 3500A should be submitted
only by the applicant whose product is the suspect drug. The suspect product is that
identified by the article=s author and is usually mentioned in the article=s title. If the
applicant believes that the suspect product is different from the one identified by the author
of the article, the applicant should indicate such information in the narrative section of the
FDA Form 3500A.
Reports of serious, unexpected adverse experiences described in the scientific literature
should be submitted for products that have the same active moiety as a product marketed
in the United States. This is true even if the excipient, dosage forms, strengths, routes of
administration, and indications vary.
When a serious, unexpected adverse experience is based on a foreign language article or
manuscript, the applicant should translate the publication into English promptly. The original
article or unpublished scientific paper and translation should be attached to the submitted
FDA Form 3500A.
B.
Postmarketing, Clinical Trial, or Surveillance Studies18
For the purposes of this section, a study refers to the systematic collection of data involving
solicitation of adverse experience information (e.g., derived from a clinical trial, patient
registry). Adverse experiences incidental to other types of studies not involving monitoring
adverse experiences of products should be treated as spontaneous reports (see Appendix
A in this guidance for definition of spontaneous report). For purposes of safety reporting,
reports of suspected adverse experiences obtained from company sponsored patient
support programs and disease management programs should be handled as if they were
study reports and not as spontaneous reports.
Serious, unexpected adverse experiences that occur during a study must be submitted as
15-day reports. These adverse experiences are only required to be reported if there is a
reasonable possibility that the drug or biological product caused the adverse experience.
18
The requirements for reporting adverse experiences from studies can be found in '' 310.305(c)(1),
314.80(c)(2)(iii), 314.80(e)(1), 600.80(c)(2)(iii), and 600.80(e)(1).
19

787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
Adverse experiences occurring with marketed drug or biological products during IND trials
must also be submitted, as prescribed under ' 312.32, to the FDA new drug review
division in the Center for Drug Evaluation and Research or the product review office in the
Center for Biologics Evaluation and Research that has responsibility for oversight of the
IND.
For each adverse experience, a suspect product should be identified. Reports from
blinded studies should be submitted only after the code is broken. The blind should always
be broken for each patient or subject that experiences a serious, unexpected adverse
experience unless arrangements have been made otherwise with the responsible FDA
review division. Exceptions to breaking the blind usually involve situations in which
mortality or certain serious morbidities are indeed the clinical endpoint. This is consistent
with the ICH E2A guidance.
C.
Foreign Reports19
Foreign reports of serious, unexpected adverse experiences must be submitted as 15-day

reports. Other foreign reports, including serious and expected, nonserious and unexpected,
and nonserious and expected adverse experiences are not required to be submitted.
Reports of foreign serious, unexpected adverse experiences should be submitted for
products that have the same active moiety as a product marketed in the United States.
This is true even if the excipient, dosage forms, strengths, routes of administration, and
indications vary. When a foreign report is submitted on a product that is not identical to a
product marketed in the United States, item C1 of FDA Form 3500A should contain the
foreign trade name, the generic name, and the NDA number for the product with the same
active moiety that is marketed in the United States.
D.
Death Reports
Death is always a serious outcome (see definition of serious in Appendix A of this

guidance and at '' 310.305(b), 314.80(a) and 600.80(a)). Thus, if death is associated
with an unexpected adverse experience, or if death is associated with an expected
adverse experience but the labeling does not specifically state that the adverse experience
may be associated with a fatal outcome, a 15-day report should be submitted.
E.
Overdose Reports
Reports of overdose should be submitted only when the overdose is associated with an
adverse experience. If the adverse experience associated with the overdose is serious
and unexpected, a l5-day report should be completed. If the adverse experience is serious
and expected, nonserious and unexpected, or nonserious and expected, a non-15 day
19
The requirements for reporting of foreign adverse experiences can be found in '' 310.305(c)(1)(i),
314.80(c)(2)(iii) and 600.80(c)(2)(iii).
20

829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
report should be submitted in the periodic report for spontaneously reported domestic
cases.
F.
Lack of Effect Reports
The definition of adverse experience includes any failure of expected pharmacological

action that is synonymous with lack of effect (see definition of adverse experience in
Appendix A of this guidance and at '' 310.305(b), 314.80(a) and 600.80(a)). All
spontaneously reported cases of a lack of effect that occur in the United States should be
reported on FDA Form 3500A and submitted in the periodic report with other adverse
experiences. The lot number of the suspect product should be included in item C6 of FDA
Form 3500A.
If the report of lack of effect is for an unapproved indication, the event should not be
reported to the FDA as an individual case safety report. Instead, this information should be
included in the narrative summary section of the periodic report.
G.
Information on the Internet
Adverse experience information that is submitted to an applicant via the Internet (e.g., email) should be reported to the FDA if the applicant has knowledge of the four basic
elements for an individual case safety report (see section IV.B in this guidance).
Applicants should review any Internet sites sponsored by them for adverse experience
information, but are not responsible for reviewing any Internet sites that are not sponsored
by them. However, if an applicant becomes aware of an adverse experience on an Internet
site that it does not sponsor, the applicant should review the adverse experience and
determine if it should be reported to the FDA.
H.
Pediatric Patients
For children under 3 years of age, the child=s date of birth and age in days or months (e.g.,
15 months) should be included under item A2 of FDA Form 3500A. The word days or
months should be clearly written. For all pediatric patients, body weight (item A4 of FDA
Form 3500A) and dose (item C2 of FDA Form 3500A) should be included.
For reports of a congenital anomaly, the age and sex of the infant should be included.
Followup reports for the infant should be considered followup to the initial report; followup
for the mother should be submitted as a new initial individual case safety report on a
separate FDA Form 3500A. The date that the congenital anomaly is detected should be
used as the event onset date (e.g., birth date of the infant, date pregnancy is terminated,
date congenital anomaly is detected by ultrasound or other diagnostic technique). This
date should be used in item B3 of FDA Form 3500A.
21
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
I.
Prescription Drugs Marketed for Human Use Without an Approved

Application20
For prescription drugs marketed for human use without an approved NDA or ANDA, all
serious, unexpected adverse experiences must be reported to the FDA on an FDA Form
3500A within 15 calendar days. These reports must be submitted in SINGLE copy under
separate cover. The report should be marked on the outside envelope "15-Day Alert
Report - 310.305." A copy of the U.S. product labeling must accompany each report.
Postmarketing periodic reports should not be submitted for these drugs.
J.
Another Applicant== s Product
Reports of adverse experiences in which the initial reporter identifies the suspect product
as one marketed by another applicant should be promptly forwarded to that applicant. An
applicant who receives a report of an adverse experience regarding one of its products
from another applicant must submit the report to the FDA within the same time constraints
applicable to any report received from a third party (see section VI.K in this guidance).
An applicant should only submit a report of an adverse experience to the FDA for a
suspect product marketed by another applicant if the applicant of the suspect product is
unknown or the report is for a serious, unexpected adverse experience occurring during the
conduct of a study.
K.
Multiple Suspect Products
If a reportable adverse experience involves two or more suspect products from the same
applicant, only one FDA Form 3500A should be completed. The FDA Form 3500A should
reference only one manufacturer report number. The report should be submitted to the
NDA, ANDA, or BLA considered most suspect by the initial reporter. If each product is
equally suspect, the report should be submitted to the product first in alphabetical order.
The adverse experience should also be reported in the narrative summary section of the
periodic report for the other product(s).
However, if one suspect product is a licensed non-vaccine biologic and the other is a
licensed vaccine, separate reporting forms should be submitted. An FDA Form 3500A
should be used for the licensed non-vaccine biologic and a VAERS form should be used
for the licensed vaccine.
If a reportable adverse experience involves two or more suspect products and two or more
applicants, an applicant may choose to submit an FDA Form 3500A to the FDA on the
adverse experience that describes detailed information including the product(s) from the
20
The requirements for prescription drugs marketed for human use without an approved application can be
found in ' 310.305.
22

914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
other applicant. In such a case, the other applicant should receive a copy of the FDA Form
3500A including its manufacturer report number so that the other applicant can reference
this report when providing any relevant followup information to the FDA. The other applicant
should not submit to the FDA information originally submitted to the Agency by the first
applicant.
L.
Suspect Drugs with Multiple NDAs or ANDAs by the Same Applicant
A drug substance can be the subject of more than one approved NDA or ANDA. If an
applicant receives a report for a drug and the specific application is identifiable, the report
should be submitted to that application. However, if a drug substance has more than one
application and it cannot be determined which of the approved applications is involved, the
report should be submitted to the application for the drug product that was approved first
and that has the same general route of administration as the suspect drug substance. This
would usually be the application with the lowest number.
M.
Two or More Marketers of a Product
If two or more companies that co-market a specific drug product have an approved NDA
for the product, one of the companies should be identified as having primary responsibility
for reporting adverse experiences for the drug product to the FDA to avoid duplicative
reporting of adverse experiences. This would also be true for two or more companies that
co-market a specific biological product and have an approved BLA for the product.
N.
Unapproved Indications
An adverse experience associated with the use of a product for an unapproved indication
should be reported to the FDA as is required for any other spontaneously reported adverse
experience occurring in the United States (e.g., 15-day report for a serious, unexpected
adverse experience or periodic report for a nonserious, unexpected adverse experience).
However, a lack of effect report for an unapproved indication should not be reported on an
FDA Form 3500A. Instead, such information should be included in the narrative summary
section of a periodic report.
O.
Product Interactions
If an applicant receives a report identified as a product interaction, each of the products

should be identified as a suspect product in item C1 of FDA Form 3500A.
P.
Reports from the FDA21
21
The requirements for submitting reports received from the FDA can be found in '' 310.305(c)(5),
314.80(b), and 600.80(b).
23

955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
Sometimes FDA forwards individual case safety reports (i.e., FDA Form 3500As) to
applicants. For example, applicants can participate in the FDAs MedWatch-toManufacturer Program. This program is designed to expedite transmission from the FDA
to applicants participating in the program cases of serious adverse experiences reported
directly to the FDA voluntarily by initial reporters (e.g., health care professionals,
consumers). Details of the program can be found on the Internet at
www.fda.gov/medwatch/report/mmp.htm.
Applicants that receive individual case safety reports from FDA are not required to
resubmit them to the Agency. However, followup information to these initial reports must
be submitted to the FDA (see section V.C in this guidance).
Q.
Product Defects
If a product defect results in an adverse experience, the adverse experience should be

reported as any other spontaneously reported adverse experience occurring in the United
States (e.g., 15-day report for a serious, unexpected adverse experience or periodic report
for a nonserious, unexpected adverse experience).
R.
Reporting Ambiguities
In some cases, it may be difficult to interpret specific criteria used for reporting. Examples
include determining whether an adverse experience is expected or unexpected or whether
a patient is identifiable or not. For these and any other ambiguities, the applicant should
use a conservative approach and err on the side of reporting the adverse experience to the
FDA. Thus, if there is doubt, consider an adverse experience to be unexpected, consider
a patient to be identifiable, and so on.
VII.
CODING OF ADVERSE EXPERIENCES IN INDIVIDUAL CASE SAFETY
REPORTS
Companies currently use a variety of medical terminologies to code adverse experiences
in individual case safety reports (e.g., COSTART, WHOART, MedDRA). At this time, the
FDA will accept adverse experiences coded with any of these terminologies. However, as
recommended by ICH, the Agency encourages companies to use MedDRA for this
purpose and as indicated in the FDAs advanced notice of proposed rulemaking on this
topic (63 FR 59746; November 5, 1998), the Agency plans to propose to require use of
MedDRA as the terminology for coding adverse experiences in individual case safety
reports submitted to the FDA.
Companies can license MedDRA from an international maintenance and support services
organization (MSSO) (toll free number 877-258-8280 (703-345-7799 in Washington D.C.
area), fax 703-345-7755, e-mail [email protected], Internet at
www.meddramsso.com).
24

1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
VIII.
REPORTING FORMATS22
Individual case safety reports of adverse experiences that occur domestically for marketed
human drugs and biological products, except vaccines, must be submitted to the FDA on
FDA Form 3500A; a VAERS form must be used for vaccines. Foreign adverse
experiences can be submitted either on FDA Form 3500A or, if preferred, on a CIOMS I
form. Foreign adverse experiences associated with the use of vaccines can be submitted
on either a VAERS form or, if preferred, a CIOMS I form. A separate FDA Form 3500A,
VAERS form, or CIOMS I form must be completed for each individual person experiencing
an adverse experience.
The following paragraphs describe how to acquire or generate the various reporting forms
for individual case safety reports and how to obtain information on FDAs pilot program for
electronic submission of these reports. This section also describes a suggested reporting
format for distribution reports for human biological products with approved BLAs.
The following abbreviations should be used when specific information is not available for
an individual case safety report or distribution report:
A.
NA for not applicable

NI for no information at this time (but may be available later)
UNK for unknown
FDA Form 3500A
See Appendix C of this guidance for a copy of the form.23
1.
Copies of the FDA Form 3500A can be obtained in the following ways:
From the Internet at www.fda.gov/medwatch/report/mfg.htm. Print the

form or download it as a PDF file. Form software can also be
downloaded and used to complete the forms using a personal
computer. Completed forms should be mailed to the FDA because
this software does not permit electronic submission of reports. The
software is also available on disk. For a copy of the disk, call 1-800FDA-1088 or send an electronic request via the MedWatch comment
page (www.fda.gov/medwatch/report/mfg.htm). Note: this software
22
The requirements for reporting formats can be found in '' 310.305(d), 314.80(f) and 600.80(f).
Instructions for completing FDA Form 3500A are available on the Internet at
www.fda.gov/medwatch/report/instruc.htm.
23
25

1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
contains both FDA Form 3500 for voluntary reporting and FDA Form
3500A for mandatory reporting.
By Fax - Call 1-800-FDA-1088 and make the following selections:

Press 1 (health professional)
Press 2 (obtain a copy of a form)
Press 4 (obtain fax of FDA Form 3500A).
By Mail - Up to 10 copies of FDA Form 3500A can be obtained from:

Office of Post-marketing Drug Risk Assessment
Center for Drug Evaluation and Research (HFD-400)
5600 Fishers Lane, Room 15B-31
Rockville, MD 20857
OR
Office of Biostatistics and Epidemiology
Center for Biologics Evaluation and Research (HFM-210)
Adverse Experience Reporting
1401 Rockville Pike
Rockville, MD 20852-1448
Additional copies can be obtained from:
Consolidated Forms and Publications Distribution Center
Washington Commerce Center
3222 Hubbard Rd.
Landover, MD 20785
2.
Copies can be created by:
Photocopying a blank FDA Form 3500A
Producing a computer-generated facsimile of FDA Form 3500A
In place of using the preprinted forms, a computer-generated facsimile of

FDA Form 3500A can be used after approval, in writing, by FDA (''
310.305(d)(3), 314.80(f)(3) and 600.80(f)(3)). This computer-generated
facsimile of FDA Form 3500A should:
a.
Contain all the elements (i.e., 2-column format, sections, blocks, titles,
descriptors within blocks, text for disclaimer) of FDA Form 3500A in
26

1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
the identical enumerated sequence of the form, except as otherwise

noted. For reports in which no suspect medical device is involved, the
box Section D. Suspect Medical Device on the front page of FDA
Form 3500A can be replaced with the box Section G. All
Manufacturers located on the back page of the form. This would allow
reporters of adverse experiences for drug and biological products to
use a one-page form for reporting. See Appendix F of this guidance
for a sample of a one-page FDA Form 3500A).
b.
Have, at least, a 1/4" margin around the entire form so that

information is not lost during scanning, copying or faxing of the
document (the left-hand margin may be increased up to 2" to permit
binding (e.g., hole-punching) of the form) (all other margins have to
continue to be at least 1/4").
c.
Include the name of the company centered on the top of the front
page.
d.
Include in the lower left corner of the front page the phrase 3500A
Facsimile instead of the phrase FDA Form 3500A (date of form [e.g.,
6/93]).
e.
Include in the upper right corner of the front page above the FDA Use
Only box the phrase FDA Facsimile Approval: [include date of
approval by FDA], instead of the phrase See OMB statement on
reverse.
f.
Have the data and text contained within the boxes on a computergenerated FDA Form 3500A conform to the following specifications:
The font size should not be less than 10 point.
A font type should be selected that is easy to read (e.g., CG

Times, Arial) and not condensed. The form may be copied or
faxed multiple times. For visual contrast, the font type used for
the data and text should, if possible, be different from the font
type used to create the FDA Form 3500A.
Have all data and text contained within each of the boxes (e.g.,
a box marked with an Ax@ should be centered within the box,
and narratives should include margins so that letters are not
obscured or made ambiguous by lines defining a box.).
27

1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
g.
Have the phrase continued included at the end of each field

that has additional information continued onto another page.
Have continuation pages containing additional information for

narrative entries conform to the following specifications:
Each page should be identified as Page _ of _.
Each page should include the manufacturer report number in

the upper right corner.
Each page should include the name of the company in the

upper right corner.
The section and block number (e.g., Block B5) for each
narrative entry should be included.
For approval of computer-generated facsimiles of FDA Form 3500As, companies

should mail their requests along with two copies of the computer-generated
facsimile, a blank one and one with all the boxes completed with sample data/text,
to:
Information Technology Staff
OPDRA/CDER/FDA Room 15B23
HFD-420
5600 Fishers Lane
Rockville, MD 20857
Companies can contact the Information Technology Staff at 301-827-3223 to check
on the status of an approval request. Companies that are using a computergenerated facsimile of FDA Form 3500A from a vendor that has already obtained
approval, in writing, from the FDA for the form do not have to submit another
approval request to the Agency (the vendor=s name and approval date should
appear in the upper right corner of the form).
B.
VAERS Form for Vaccines

See Appendix D of this guidance for a copy of the form.24
24
A guidance for industry entitled How to Complete the Vaccine Adverse Event Reporting System Form
(VAERS-1) (October 1999) is available on the Internet at www.fda.gov/cber/guidelines.htm or from the Office
of Communication, Training and Manufacturers Assistance (HFM-40), CBER, 1401 Rockville Pike, Rockville,
MD 20852-1448, (Fax) 1-888-CBERFAX or 301-827-3844, (Voice Information) 1-800-835-4709 or 301-8271800.
28

1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1.
Copies of the VAERS form can be obtained by calling 1-800-822-7967.
2.
In place of using the preprinted forms, a computer-generated facsimile of the

VAERS form can be used after approval, in writing, by FDA (' 600.80(f)(3)).
To request approval of a computer-generated facsimile of a VAERS form, a
printed copy with data to illustrate how each data field will be reported should
be submitted to:
Office of Biostatistics and Epidemiology (HFM-210)
Center for Biologics Evaluation and Research, FDA
1401 Rockville Pike
C.
CIOMS I Form for Foreign Adverse Experiences
CIOMS, working with several member nations and industry, has developed a format for
international adverse experience reporting (CIOMS I form) (see Appendix E of this
guidance). Applicants can use an FDA Form 3500A or, if preferred, a CIOMS I form for
submission of 15-day reports of foreign adverse experiences to the FDA. Applicants
cannot use a CIOMS I form for submissions of adverse experiences that occur within the
United States. For these adverse experiences, an FDA Form 3500A must be used.
D.
This section on distribution reports only applies to human biological products with
approved BLAs. Under ' 600.81, distribution reports must include the bulk lot, fill lot, and
label lot numbers for the total number of dosage units of each strength or potency
distributed (e.g., 50,000 per 10-milliliter vials), labeled date of expiration, and date of
distribution of fill lot or label lot. The report must also include information about any
significant amount of a fill lot or label lot that may have been returned.
The regulations do not specify a reporting form or format for distribution reports. One
suggested report format is shown here:
Product name, strength

Product Code
Biologics License No.
Bulk Lot
No.
Fill Lot
No.
Label Lot
No.
Expiration
Date
1204
29
Distribution
Date
No. of Doses
Distributed
No. of Doses
Returned

1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
If there is more than one distribution date for a lot, the report should include each
distribution date and the number of doses distributed. When reporting returned doses, the
number of doses distributed should not be repeated.
For vaccines, if available, distribution of doses can be reported by public, private, or
military sectors.
E.
Electronic Submissions
The FDA is in the process of developing a system for electronic submission of

postmarketing safety reports. At this time, applicants can submit, under a pilot program,
certain individual case safety reports electronically. Details of this pilot program are
available on the Internet at www.fda.gov/cder/aerssub. The Agency also plans to have a
system for electronic submission of distribution reports for biological products including
vaccines in the near future.
IX.
HOW AND WHERE TO SUBMIT POSTMARKETING SAFETY REPORTS
All submissions should be legible and typewritten with a minimum acceptable font size of
10 point. Legible photostatic copies can be submitted. However, visual contrast should be
adequate to ensure clear readable archival images. The applicant must submit one or two
copies of each safety report as specified in this section unless a waiver is granted
permitting a different number of copies (see section XI in this guidance).
A.
Human Drug Products

1.
For prescription drugs marketed for human use without an approved NDA
or ANDA, postmarketing 15-day reports (initial and followup) should be sent
as single copies to:
Office of Post-marketing Drug Risk Assessment (HFD-400)
Center for Drug Evaluation and Research
5600 Fishers Lane
Rockville, MD 20857
2.
For drugs with approved ANDAs, postmarketing 15-day reports, (initial and
followup), and periodic reports should be sent as single copies to:
Office of Post-marketing Drug Risk Assessment (HFD-400)
5600 Fishers Lane
30

1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
Rockville, MD 20857
3.
For drugs with approved NDAs, postmarketing 15-day reports (initial and
followup), and periodic reports should be sent in duplicate to:
Central Document Room
12229 Wilkins Ave.
Rockville, MD 20852
B.
Human Biological Products and Vaccines

1.
For vaccines, postmarketing 15-day reports (initial and followup), and

periodic reports should be sent in duplicate to:
VAERS
P.O. Box 1100
2.
For biological products other than vaccines, postmarketing 15-day reports

(initial and followup) and periodic reports should be sent in duplicate to:
Adverse Experience Reporting
1401 Rockville Pike
3.
For all biological products and vaccines, distribution reports (' 600.81)
should be sent in duplicate to:
Distribution Reports
1401 Rockville Pike
X.
WRITTEN PROCEDURES FOR POSTMARKETING SAFETY REPORTING
Each applicant must develop written standard operating procedures for the surveillance,
receipt, evaluation, and reporting of adverse experiences to the FDA ('' 310.305(a),
314.80(b) and 600.80(b)). The FDA will consider an applicant responsible for information
known to its employees, affiliates, and contractors. For this purpose, applicants should
31

1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
develop procedures that allow for expedited handling of adverse experience reports.
Records of due diligence should be maintained. This applies to surveillance and
processing for both domestic and foreign reports of adverse experiences.
XI.
REQUESTS FOR WAIVERS TO POSTMARKETING SAFETY REPORTING

REQUIREMENTS
Under '' 314.90(a) and 600.90(a), applicants may ask the FDA to waive any
postmarketing safety reporting requirement that applies to the applicant under '' 314.80
and 600.80. The following paragraphs discuss certain postmarketing periodic safety
reporting requirements for which the FDA is currently granting waivers.
A.
Submission of FDA Form 3500A for Nonserious, Expected Adverse
Experiences
Applicants are encouraged to request a waiver for submission of FDA Form 3500As for
individual case safety reports of nonserious, expected adverse experiences that, at a
minimum, contain the four basic elements (see section IV.B in this guidance). In such
cases, applicants should maintain records of these nonserious, expected adverse
experiences in their corporate drug or biological product safety files. The FDA may
request that an applicant submit to the Agency FDA Form 3500As of one or more of these
adverse experiences. The agency would expect these forms to be submitted within 5
calendar days after receipt of the request.
Applicants who obtain a waiver for the requirement to submit individual case safety reports
of nonserious, expected adverse experiences would still be expected to submit information
on these adverse experiences to the FDA in the summary tabulations section of
postmarketing periodic reports (see section V.B.2.a in this guidance).
At this time, the FDA does not intend to grant waiver requests for new biological molecular
entities within one year of licensure or for blood products, plasma derivatives, or vaccines.
The Agency believes that it is important to continue periodic review of all individual case
safety reports of adverse experiences for these products to identify safety problems due to
lot-to-lot variations and also to monitor the safety of newly approved biological products.
B.
Submission of PSUR format for the Periodic Report
Applicants can request a waiver of the requirement to submit postmarketing periodic

safety reports in the format described in the regulations. Instead, applicants can prepare
these reports using the PSUR (Periodic Safety Update Report) format described in the
ICH E2C guidance. In addition, the Agency recommends the following:
If all dosage forms and formulations for the active substance, as well as
indications, are combined in one PSUR, this information should be
32

1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
separated into specific sections of the report when such separation is

appropriate to accurately portray the safety profile of the specific dosage
forms. For example, one should not combine information from ophthalmic
drop dosage forms and solid oral dosage forms. One copy of the PSUR
should be submitted for each approved NDA or ANDA whose product is
covered in the PSUR as well as an additional copy for review by the
postmarketing pharmacovigilance office.
C.
Copies of the FDA Form 3500A or VAERS form that are required by the
regulations must be included. 25 These forms should be included with the
PSUR as an appendix. You can request a waiver for submission of certain
nonserious, expected adverse experiences on an FDA Form 3500A as
described in the previous section.
A summary tabulation should be included as an appendix listing all

spontaneously reported U.S. individual case safety reports from consumers if
such cases are not already included in the PSUR. Summary tabulations
should be presented by body system of all adverse experience terms and
counts of occurrences and be segregated by type (i.e., serious/unexpected;
serious/expected; nonserious/unexpected; and nonserious/expected),
A narrative should be included as an appendix that references the changes,

if any, to the approved U.S. labeling for the dosage forms covered by the
PSUR based on new information in the PSUR. A copy of the most recently
approved U.S. labeling for the product(s) covered by the PSUR should be
included.
Submission Date and Frequency for PSUR Reports
Applicants can request a waiver to submit PSURs to the FDA based on the month and day
of the international birth date of the product instead of the month and day of the anniversary
date of U.S. approval of the product.26 The waiver request should specify that these
PSURs would be submitted to the FDA within 60 calendar days of the data lock point (i.e.,
month and day of the international birth date of the product or any other day agreed on by
the applicant and the FDA).27
Applicants can also request a waiver to submit PSURs to the FDA at a frequency other
than those required under 314.80(c)(2)(i) and 600.80(c)(2)(i).
25
See '' 314.80(c)(2)(ii)(b) and 600.80(c)(2)(ii)(B).

The international birth date for a product is the date the first regulatory authority in the world approved the
first marketing application for a human drug product containing the drug substance or a human biological
product.
26
27
The data lock point is the date designated as the cut-off date for data to be included in a PSUR.
33

1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
D.
How and Where to Submit Waiver Requests

1.
Marketed human drug products
For waivers under ' 314.90(a), applicants should submit a written waiver request
(include the products name(s), date(s) of U.S. approval, and the application
number(s)) to:
Director
Office of Post-Marketing Drug Risk Assessment
5600 Fishers Lane, HFD-400
Rockville, MD 20857
2.
Licensed biological products
For waivers under ' 600.90(a), applicants should submit a written waiver request
(include the product name(s), date(s) of U.S. approval, and the application
number(s)) to:
Director
Office of Biostatistics & Epidemiology
Center for Biologics Evaluation and Research
140l Rockville Pike, HFM-220
XII.
VALIDATION OF ADVERSE EXPERIENCE COMPUTER SYSTEMS
If an electronic record of an adverse experience is created, modified, maintained,

archived, retrieved, or transmitted, the applicant is required, among other things, to employ
procedures to ensure that records are trustworthy, reliable, and consistent with FDA's
ability to promote and protect public health (21 CFR part 11). Those procedures must
include validation of systems to ensure accuracy, reliability, consistent intended
performance, and the ability to discern invalid or altered records.
34

1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
APPENDIX A: GLOSSARY
Adverse Experience - Any adverse event associated with the use of a drug or biological
product in humans, whether or not considered product-related, including the following: An
adverse event occurring in the course of the use of a drug product in professional practice;
an adverse event occurring from drug overdose whether accidental or intentional; an
adverse event occurring from drug abuse; an adverse event occurring from drug
withdrawal; and any failure of expected pharmacological action. Reporting an adverse
experience does not necessarily reflect a conclusion by the applicant or the FDA that the
product caused or contributed to the adverse experience. Adverse experience is
synonymous with adverse drug experience, adverse biological experience, adverse
product experience, and adverse event.
Affiliate - Any individual or entity related by employment or organizational structure to the
applicant, including all subsidiaries, whether domestic or foreign.
Applicant - An individual or entity who holds the new drug application (NDA), abbreviated
new drug application (ANDA), or the biologics license application (BLA). For purposes of
this guidance, this term includes any person whose name appears on the label of a
marketed drug or licensed biological product as its manufacturer, packer, distributor,
shared manufacturer, joint manufacturer, or any participant involved in divided
manufacturing.
Causality Assessment - Determination of whether there is a reasonable possibility that
the product is etiologically related to the adverse experience. Causality assessment
includes, for example, assessment of temporal relationships, dechallenge/rechallenge
information, association with (or lack of association with) underlying disease, presence (or
absence) of a more likely cause, and physiologic plausibility.
Challenge - Administration of a suspect product by any route.
Dechallenge - Withdrawal of a suspect product from a patient's therapeutic
regimen.
Negative Dechallenge - Continued presence of an adverse experience after
withdrawal of the suspect product.
Positive Dechallenge - Partial or complete disappearance of an adverse
experience after withdrawal of the suspect product.
Rechallenge - Reintroduction of a suspect product suspected of having caused an
adverse experience following a positive dechallenge.
35

1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
Negative Rechallenge - Failure of the product, when reintroduced, to produce

signs or symptoms similar to those observed when the suspect product was
previously introduced.
Positive Rechallenge - Reoccurrence of similar signs and symptoms upon
reintroduction of the suspect product.
Disability - A substantial disruption in one's ability to conduct normal life functions.
Expected Adverse Experience - Adverse experience listed in the current FDA-approved
labeling for the drug or licensed biological product. This would include any section of the
labeling that refers to adverse experience information.
Initial Reporter - The original source of information concerning an adverse experience
(e.g., consumer, healthcare professional).
Life-threatening Adverse Experience - An adverse experience that, in the view of the
initial reporter, places the patient at immediate risk of death from the adverse experience
as it occurred. It does not include an adverse experience that, had it occurred in a more
severe form, might have caused death.
Serious Adverse Experience - An adverse experience occurring at any dose that results
in any of the following outcomes:
Death
Life-threatening adverse experience
Initial inpatient hospitalization
Prolongation of hospitalization
Significant or persistent disability/incapacity
Congenital anomaly/birth defect (including that occurring in a fetus);
Important medical events, based upon appropriate medical judgment, that may
jeopardize the patient or subject and may require medical or surgical intervention to
prevent one of the outcomes listed above.
Spontaneous Report - A communication from an individual (e.g. health care

professional, consumer) to a company or regulatory authority that describes a suspected
adverse experience. It does not include cases identified from information solicited by the
applicant such as individual cases or findings derived from a study.
36

1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
Study - Any organized data collection system (e.g., adverse experience information
derived from a clinical trial, patient registry including pregnancy registries). Reports from
company sponsored patient support programs and disease management programs should
be handled as if they were study reports and not as spontaneous reports.
Suspect Product - Drug or biological product associated with an adverse experience as
determined by the initial reporter, regardless of the opinion of the applicant.
Unexpected Adverse Experience - Adverse experience not included in any section of
the current FDA-approved labeling for the drug or licensed biological product. This
includes an adverse experience that may differ from a labeled adverse experience
because of greater severity or specificity (e.g., abnormal liver function versus hepatic
necrosis). Adverse experiences listed as occurring with a class of drugs or biological
products but not specifically mentioned with a particular drug or biological product are
considered unexpected (e.g., rash with antibiotic X would be unexpected if the labeling
said "rash may be associated with antibiotics"). This is because the labeling does not
specifically state "rash is associated with antibiotic X." Reports of death from an adverse
experience are considered unexpected unless the possibility of a fatal outcome from that
adverse experience is stated in the labeling.
37

1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
APPENDIX B: REPORT CHECKLIST

Before mailing your postmarketing safety reports to the FDA, you should make sure that
the following questions have been addressed:
A.
For All FDA Form 3500A Reports

l.
Have you completed a separate FDA Form 3500A for each patient?
2.
Have you included the manufacturer report number in item G9 on FDA Form
3500A? (Note: For followup reports, this number should be identical to the
manufacturer report number on the initial report.)
3.
Have you clearly marked the report "Periodic" or "15-Day" as appropriate in

item G7 on FDA Form 3500A?
4.
Have you clearly marked the report "Initial" or "Followup" as appropriate in

item G7 on FDA Form 3500A? Do not package and send a 15-day followup
report with a non-15 day followup report.
5.
Have you included the name, address, and telephone number of the initial
reporter in item E1 on FDA Form 3500A?
6.
Have you left all the boxes in item B2 of the FDA Form 3500A blank for a
nonserious adverse experience? A box should only be checked in item B2 if
the outcome for the adverse experience is serious.
7.
Have you included all relevant attachments and eliminated unnecessary

attachments?
Attachments can include copies of:
hospital discharge summaries

autopsy/biopsy reports
death certificates
relevant office visit notes
summaries of relevant laboratory tests and other diagnostic
procedures, particularly pre- and post-drug values.
Each page of an attachment should identify the manufacturer report number (i.e.,
reported in item G9 on FDA Form 3500A) for that case.
In general, attachments should not include:
lengthy legal records

38

1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
8.
9.
B.
complete medical records
If two or more products produced by your company were suspected by the

initial reporter:
Have you completed only one FDA Form 3500A? (You should not
prepare more than one FDA Form 3500A even if more than one of
the suspect products was produced by your company.)
Have you identified all the suspect products in item C1 on FDA Form
3500A?
Have you indicated on FDA Form 3500A the product considered

most suspect by the initial reporter and prepared the report
accordingly? (If the initial reporter ranked them equally, you should
submit an FDA Form 3500A to the file of the first suspect product in
alphabetical order. You should list the adverse experience(s) for each
of the other suspected product(s) in the narrative summary section of
the periodic report.)
Have you completed an FDA Form 3500A for another applicant's drug?
(You should send the report to the FDA if the applicant of the suspect product
is unknown or the report is for a serious, unexpected adverse experience
occurring during the conduct of a study. For all other cases, you should send
the report to the applicant holder of the suspect drug and not to the FDA.)
For 15-Day Reports

1.
Have you clearly marked "15-Day Report" in item G7 on the FDA Form
3500A?
2.
Have you packaged the 15-day report (FDA Form 3500A initial or followup)
separately? (Do not package and send an initial 15-day report with a 15-day
followup report. You should not submit copies of 15-day reports with a
periodic report.)
3.
Have you submitted the report in duplicate? (Exceptions: for prescription

drugs marketed for human use without an approved application and for drugs
with approved ANDAs, only a single copy should be sent.)
4.
Have you clearly marked the outside mailing envelope "15-Day Report?
39

1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
C.
D.
For Periodic Reports

1.
Have you included the four types of information required for a periodic report
and clearly separated the four sections with marked tabs?
2.
Have you submitted the report in duplicate? (Exception: For drugs with
approved ANDAs, only a single copy should be sent).
3.
Have you eliminated all unnecessary attachments to FDA Form 3500As?
For Followup Reports

l.
Have you included the manufacturer report number in item G9 on FDA Form
3500A? (Note: this number should be identical to the manufacturer report
number on the initial report).
2.
Have you marked Afollowup@ in item G7 on FDA Form 3500A and indicated
what number followup report it is?
40

USFDA Guidance For Industry - PSUR

Uploaded by

Copyright:

Available Formats

USFDA Guidance For Industry - PSUR

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

USFDA Guidance For Industry - PSUR

Uploaded by

Copyright:

Available Formats

Guidance for Industry

Postmarketing Safety Reporting

U.S. Department of Health and Human Services

Guidance for Industry

Drug Information Branch (HFD-210)

U.S. Department of Health and Human Services

W HAT DOES THIS GUIDANCE DISCUSS?.......................................................................................................................... 1

FINAL RULES ....................................................................................................................................................................... 3

WHO MUST REPORT.........................................................................................................................................................4

WHAT DO I REPORT? .......................................................................................................................................................5

TYPE OF A DVERSE EXPERIENCES ..................................................................................................................................... 6

15-DAY REPORTS OF SERIOUS , UNEXPECTED A DVERSE EXPERIENCES ........................................................................ 9

CODING OF ADVERSE EXPERIENCES IN INDIVIDUAL CASE SAFETY REPORTS ..................................24

FDA FORM 3500A........................................................................................................................................................... 25

ELECTRONIC SUBMISSIONS .............................................................................................................................................. 30

WRITTEN PROCEDURES FOR POSTMARKETING SAFETY REPORTING.......................................................31

REQUESTS FOR WAIVERS TO POSTMARKETING SAFETY REPORTING REQUIREMENTS ....................32

Draft Not for Implementation

Guidance for Industry1

Postmarketing Safety Reporting for Human Drug and

Serious and expected

What Does This Guidance Discuss?

Draft Not for Implementation

15-Day Reports of Serious, Unexpected Adverse Experiences

What Does This Guidance Not Discuss?

IND Safety Reports (21 CFR 312.32)4

This guidance does not apply to the following products:

In vitro diagnostic products

Good Guidance Practices

IND means investigational new drug application

Draft Not for Implementation

Expedited Safety Reports for Human Drug and Biological Products

Postmarketing Expedited Increased Frequency Reports for Human Drug and

Postmarketing Reporting of Adverse Drug Experiences (March 1992)

Draft Not for Implementation

Guideline for Adverse Experience Reporting for Licensed Biological

Postmarketing Adverse Experience Reporting for Human Drug and

WHO MUST REPORT

Manufacturers are required to submit postmarketing expedited safety reports to the

Draft Not for Implementation

Licensed manufacturers (individual or corporate entity that holds a BLA) are

Draft Not for Implementation

Type of Adverse Experiences

Other Spontaneously Reported Adverse Experiences (Domestic Only)9

Adverse experiences occurring in the United States from commercial marketing

serious and expected

Serious Adverse Experiences10

Draft Not for Implementation

The outcome of an adverse experience must be determined before a report can be

A patient admitted to a hospital for 1 or more days as a result of an adverse

Draft Not for Implementation

Unexpected and Expected Adverse Experiences11

Spontaneous reports are unsolicited communications from individuals (e.g., health

Data Elements to Include in a Postmarketing Individual Case Safety Report

See Appendix A for definition of spontaneous report.

An applicant that is actively seeking information on an adverse experience should use

15-Day Reports of Serious, Unexpected Adverse Experiences13

Draft Not for Implementation